Image
Our research group is focused on refining pre-clinical models to study treatment resistance to novel targeted therapies against bladder and prostate cancer. We leverage high throughput, genome wide CRISPR screens to examine drug resistance and identify regulation of surface target expression. In collaboration with the Department of Urology at UCSF, we are developing a robust biobank of patient derived tumor tissues including fresh and archival tissue. We are conducting correlative studies in neoadjuvant clinical trials for high risk prostate cancer for future biomarker and model development.
